Tag: Personalised Medicine
-
Ireland Advances Phase 2 of National Precision Oncology Program to Personalize Cancer Care
Ireland launches Phase 2 of its national precision oncology program On 8 October, Ireland marked a significant milestone in its fight against cancer as Minister for Further and Higher Education, Research, Innovation and Science James Lawless TD unveiled Phase 2 of Precision Oncology Ireland (POI). This country-wide effort stands as the largest and most ambitious…
-
Ireland Expands Precision Oncology Ireland: Phase 2 Launch Poised to Transform Cancer Care
Ireland Launches Phase 2 of its National Precision Oncology Program On 8 October, Ireland marked a significant milestone in its fight against cancer with the launch of Phase 2 of Precision Oncology Ireland (POI). The event signals a bold expansion of the country’s leading cancer research program, built to advance personalised cancer research and patient…
-
Advancing Gene Editing: How Lipid Nanoparticles Are Shaping CRISPR Delivery
Introduction: The delivery bottleneck in CRISPR therapies CRISPR-based medicines hold the promise of treating a wide range of diseases, but their success hinges on effective delivery. Early efforts relied on viral vectors, especially adeno-associated viruses (AAVs), to ferry genetic material. While AAVs can deliver DNA, their payload size is limited and пациентов often develop immune…
-
Ireland launches phase 2 of €28m Precision Oncology Ireland programme to accelerate personalised cancer care
Phase 2 kicks off for Ireland’s largest cancer research initiative Ireland’s leading cancer research programme, Precision Oncology Ireland (POI), has received a €28 million co-funding boost to move into its second phase. The expansion aims to scale the collaborative model established in POI’s inaugural phase and to deepen ties between researchers, clinicians, industry partners, charities,…
-
Living with cancer in Ireland: We’ve moved from a one-size-fits-all treatment
From uniform treatments to personalised cancer care In Ireland, the cancer treatment landscape has shifted dramatically over the last decade. Patients who once faced a one-size-fits-all approach now benefit from personalised strategies that target the biology of their disease. For Lydia Whelan, a 32-year-old diagnosed with stage 2 HER2+ breast cancer in 2024, this evolution…